| 1. |
Hyperhidrosis prevalence has economic implications in the US |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
A consensus statement that addresses the recognition, diagnosis and management of patients with primary focal hyperhidrosis has been published, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Pharmacoeconomic news from the Annual European Congress of Rheumatology |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 4-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Memantine cost saving in moderately-severe to severe AD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Clopidogrel cost effective for prevention of vascular events? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Iguratimod: novel DMARD promising for rheumatoid arthritis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 7-7
S Sullivan,,
Preview
|
|
摘要:
Iguratimod [T 614, Careram] is a novel DMARD expected to be a useful treatment for patients with rheumatoid arthritis. A phase III study presented at the European League Against Rheumatism (EULAR) congress [Berlin, Germany; June 2004] showed that iguratimod had comparable efficacy and safety to sulfasalazine. Iguratimod was also effective among patients with an insufficient response to other DMARDs. It is expected that iguratimod will have a broad application, as a first-line agent and for patients who have not responded to other DMARDs.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Leptin replacement therapy may be effective in the long-term treatment of patients with lipoatrophic diabetes mellitus, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Statins improve survival of patients with PAD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
The testosterone buccal system [Striant] is an effective testosterone-replacement treatment for men with hypogonadism, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Orlistat weighs in against obesity in adolescents |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1450,
2004,
Page 11-11
RM Poole,
Preview
|
|
摘要:
Orlistat [Xenical] is an effective weight management agent for overweight adolescents, according to a study presented at the 13th European Congress on Obesity [Prague, Czech Republic; May 2004]. This one-year study showed that treatment with orlistat, in addition to lifestyle modification, produced significant reductions in body mass index (BMI), waist circumference and fat mass, compared with lifestyle modification alone.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
